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density deficits in plaque-bearing Alzheimer model mice
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Medical School, Charlestown, MA 02129
Abstract
Synapse loss is the strongest correlate of cognitive decline in Alzheimer’s disease, and synapses
are an attractive therapeutic target due to their plastic nature that allows for potential recovery with
intervention. We have previously demonstrated in transgenic mice that form senile plaques that
dendrites surrounding plaques become dystrophic and lose postsynaptic dendritic spines.
Furthermore, we found strong evidence that plaque-associated dendritic changes are mediated by
calcineurin, a calcium-dependent phosphatase involved in cell signaling, using in vitro models and
genetically encoded inhibitors in mouse models. In this study, we pharmacologically inhibited
calcineurin with FK506 treatment to test the hypothesis that calcineurin inhibition will allow
recovery of plaque-associated synapse loss. We found that in plaque bearing transgenic mice,
short term (1 week) FK506 treatment results in an amelioration of dendritic spine loss. We also
observe an effect on spine morphology in wild-type mice with FK506 treatment. These data show
that systemic FK506 administration, and hence calcineurin inhibition, may be neuroprotective for
amyloid beta induced synaptic alterations.
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Introduction
Morphological alterations in neurons in the Alzheimer disease (AD) brain including neurite
curvature, dystrophic neurite swelling, and synapse and dendritic spines loss are thought to
contribute to cognitive decline. In both Alzheimer’s disease and mouse models, dendritic
spine loss is particularly severe near amyloid plaques, which are composed largely of
amyloid beta (Aβ) (Moolman et al., 2004; Spires et al., 2005). Simplification of the dendritic
arbor has also been observed in AD mouse models (Alpar et al., 2006), which could
contribute to dysfunction in learning and memory (Poirazi and Mel, 2001). Aβ is toxic to
synapses and disrupts cognitive function (Cleary et al., 2005; Rowan et al., 2004), thus it
may underlie dendritic spine loss near plaques. Snyder et al elegantly showed in cultured
cortical neurons that Aβ promotes endocytosis of NMDA receptors, and that this requires
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α7-nAchRs and downstream pathways including calcineurin activation (Snyder et al., 2005).
Although Aβ is a strong candidate for causing synapse loss around plaques, other plaque
associated agents could also contribute including free radicals and microglial activation
(Garcia-Alloza et al., 2006; Meyer-Luehmann et al., 2008).
We have recently observed that calcineurin mediates Aβ-induced morphological changes
including spine loss and dendritic simplification in cultured neurons and that inhibition of
calcineurin in AD model mice with a genetically encoded inhibitor can reverse plaque-
associated pathologic alterations in dendrites and dendritic spines (Wu et al., 2010). Here we
sought to test whether pharmacological inhibition of calcineurin with FK506, a commonly
used, FDA approved drug, can also cause recovery of morphological alterations in AD
model mice, since this would be a potential route for therapeutic intervention in AD. Our
previous study injecting virus into the brain to inhibit calcineurin had beneficial effects but
clearly is not a viable therapeutic administration route for humans. It has been reported
previously that injection of FK506 has restored some cognitive function in AD mouse
models (Dineley et al., 2007), which could be explained by recovery of dendritic spines.
Calcineurin is also known to play critical roles in long term potentiation and long term
depression phenomena in slice cultures, and manipulation of calcineurin impacts learning
and memory in mouse models (Dineley et al., 2010; Klee et al., 1979; Winder and Sweatt,
2001).
Calcineurin inhibitor FK506 (tacrolimus), acts via the complex of FK506 and FK506-
binding protein binding to calcineurin to prevent calcineurin-mediated dephosphorylation
(Schreiber and Crabtree, 1992). It is a commonly used immunosuppressant to combat graft
versus host disease after transplant surgery (1994); however, serious neurological side
effects occur in over 10% of FK506 treated patients including tremor, aphasia, cortical
blindness, hallucinations, and memory impairment (Lee et al., 2008; Wijdicks et al., 1994).
Thus we also investigated the effects of FK506 on non-transgenic mice to ensure that any
benefits seen in plaque-bearing mice would not come with the risk of serious side effects.
We find a recovery of dendritic spine density on cortical pyramidal neurons with one week
of systemic FK506 administration, confirming a role for calcineurin in the synaptotoxic
cascade associated with amyloid beta. We also observe changes in spine morphology in
wild-type brain with this treatment, providing a morphological correlate to changes in
learning and memory previously reported.
Materials and Methods
FK506 treatment of mice
Mice expressing yellow fluorescent protein (YFP) in a subset of pyramidal neurons (Feng et
al., 2000), and mice expressing AD-associated amyloid precursor protein and presenilin 1
(Jankowsky et al., 2001) as well as YFP (YFP-APP/PS1) from Jackson laboratories (Bar
Harbor, ME) were group housed in standard rodent cages with ad libitum access to water
and mouse chow. YFP-APP/PS1 mice were aged between 17 and 20 months and YFP mice
were aged between 18 and 33 months. A bolus of 0.1 mL/ 10g of mouse of 10mg/mL FK506
(Sigma Aldrich, St. Louis, MO - dissolved in 10% ethanol with 1% tween 80 in PBS
(Butcher et al., 1997)), vehicle (10% ethanol with 1% tween 80 in PBS without drug), or no
treatment was administered i.p. daily for 7 days. We saw no difference between vehicle
treated and untreated animals in any parameters measured so they are grouped together. We
have four groups (two genotypes and two treatment paradigms). An average of 5 animals
were treated per group with an average of 138 dendrites and 2414 spines analyzed per group
(see table 1 for exact numbers in each group).
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Tissue Preparation, imaging, and image analysis
Mice were placed in a CO2 chamber until they stopped breathing then perfused using PBS
followed by 4% paraformaldehyde and 0.1% Gluteraldehyde in PBS. Brains were kept in
fixative solution at 4° C for 48 hours. Before cutting brains were switched to 30% sucrose
for a further 48 hours. 50 µm frozen sections were cut on a Microm HM400 freezing
microtome and mounted on glass slides. Plaques were stained with thioflavin S (Sigma) in
50% ethanol for 8 minutes followed by differentiation in 80% ethanol for 10 seconds. Image
stacks (90µm × 90µm × 5–10µm with a z step 0.5 µm – 25× zoom 4, NA 0.8) of apical and
basal dendritic segments from cortical layer II–III pyramidal neurons were acquired on a
Zeiss LSM510 confocal/multiphoton microscope using laser excitation at 488nm for YFP,
2-photon excitation at 800nm for thioflavin S, and 543nm for smi312 staining with Cy3
conjugated secondary. Dendrite selection was made without regard to plaque proximity (in a
different channel so plaques were not visible). Branches off of apical dendrites and basal
dendrites were selected based on the ability to visualize more than 20 micron length of
dendrite. Using Image J, the distance of each dendrite segment to the nearest plaque (if
present) was measured. Neuron studio (Rodriguez et al., 2008) was used to automatically
detect dendrites and dendritic spines (including length and morphological class) and an
observer blind to treatment and genotype corrected any mis-detected spines. Linear spine
density and spine length were calculated. Dystrophic neurites (swellings greater than 5 µm
in diameter) were outlined in z-projections in image J and the area measured. The mean
dystrophy area was calculated for each animal (n=3 animals, 283 dystrophies in FK506
treated mice and 5 animals, 451 dystrophies in vehicle treated mice).
Data analysis
For dendritic spine density and length data, normality of data was confirmed using a
Shapiro-Wilkes test. 2-way ANOVAs with genotype and treatment as independent variables
and post-hoc Tukey-Kramer tests were used to asses the effects of treatment on the two
genotypes. Data are presented as means (of all dendrites per group in the case of spine
density and all spines per group in the case of spine length) with associated standard
deviations as previously published (Spires et al., 2005). Animals within groups did not
significantly differ as assessed by one-way ANOVA. For spine morphology data,
contingency table analyses were used to compare all spines in each treatment group.
Results
To test the hypothesis that pharmacological inhibition of calcineurin ameliorates
morphological degeneration of neurons associated with amyloid pathology, we treated mice
that express YFP in a subset of pyramidal neurons and YFP mice that also express mutant
human APP and presenilin 1 with FK506 daily for 7 days. FK506 treatment was not
associated with morbidity. YFP filled neurons were examined near and far from plaques
using confocal microscopy (figure 1), and dendritic spine density, length, and shape were
measured in image stacks. We observe a 14% decrease in dendritic spine density in YFP-
APP/PS1 mice treated with vehicle compared to YFP mice treated with vehicle (figure 2a,
p=0.0005 Tukey-Kramer post-hoc comparison). This decrease in spines is exacerbated near
plaques (figure 2b, significant correlation of 0.2678 of spine density with distance of the
dendrite from a plaque vehicle p=0.0037 Spearman’s rho test). We have observed similar
decreases of spine density in proximity to plaques in other mouse models (Spires-Jones et
al., 2007;Spires-Jones et al., 2009;Spires et al., 2005). With FK506 treatment, spine density
significantly increases by 8.5% in YFP-APP/PS1 mice compared to YFP-APP/PS1 treated
with vehicle (p=0.0381 Tukey-Kramer post-hoc comparison) bringing spine density back
close to control levels (FK506 treated YFP-APP/PS1 density is not significantly different
from YFP vehicle treated or YFP FK506 treated spine density). There is still a significant
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correlation between plaque distance and spine density (0.2653 p=0.0089). Since dendritic
spines form the postsynaptic element of the majority of excitatory synapses in cortex and
they are lost in AD and mouse models, these results show that 7 days of FK506 treatment is
beneficial in terms of reversing synapse loss.
While the number of dendritic spines scales with synapse number, the morphology of
dendritic spines affects the integration of synaptic inputs by controlling the passive flow of
depolarization from the site of the synapse at the spine head into the parent dendrite. Thus
we also examined dendritic spine morphology (length and shape classification) in FK506
treated mice (figure 3). We found that at baseline, YFP-APP/PS1 mice have shorter spines
than YFP mice in the vehicle treated condition (p=0.0051 post-hoc Tukey-Kramer test). This
agrees with an observed differential distribution of spine shapes in YFP-APP/PS1 mice with
more of the shorter stubby spines and less of the longer thin and mushroom shaped spines
(contingency table analysis Pearson’s test p=0.0004).
FK506 treatment does not affect spine length in YFP-APP/PS1 mice. However, we detected
a decrease in spine length in YFP mice without the APP and PS1 transgenes (p<0.0001 post-
hoc Tukey-Kramer test). FK506 treatment also does not have an effect on the morphology of
YFP-APP/PS1 spines but does significantly alter the YFP spines to have more stubby and
fewer thin and mushroom spines (contingency table analysis Pearson’s test p<0.0001).
Dystrophic swellings of axons and dendrites around senile plaques have been observed in
AD and mouse models and can be reversed by removing Aβ with antibody treatment or by
treatment with genetically encoded calcineurin inhibitors (Spires-Jones et al., 2009; Wu et
al., 2010). We measured the cross-sectional area of YFP positive dystrophic swellings and
found no difference in size of plaque-associated dystrophies with FK506 treatment (figure
4). Since YFP is expressed only in a subset of neurons, we used immunohistochemical
staining with an axonal neurofilament marker to assess the number of dystrophic axonal
swellings per plaque and found that this was also unchanged with FK506 treatment (figure
4). This could indicate that our treatment was not long enough to reverse dystrophic swelling
or that the concentration of drug was not high enough for this effect.
Together these data indicate that 1 week of FK506 treatment is sufficient to have beneficial
effects on dendritic spine density in APP/PS1 mice, particularly far from plaques; however,
these benefits did not extend to spine length, spine morphology, or dystrophic swellings.
Further, we observed effects of FK506 treatment on spine length and morphology in healthy
mice.
Discussion
Despite the strong correlation between synapse loss and cognitive decline in AD, very few
treatments have been found to cause recovery of synaptic loss. Removing amyloid β with
immunotherapy causes rapid recovery of synaptic structural plasticity (Spires-Jones et al.,
2009) longer-term increases in synaptic proteins (Rozkalne et al., 2009), and improvements
in cognition (Lee et al., 2006) in mice with established plaque pathology, indicating that
amyloid β contributes to synapse loss and that removing it allows synaptic recovery. We
have previously observed that constitutively active calcineurin expressed in wild-type brain
using gene transfer causes spine loss, neurite curvature, and dystrophic swellings, while
expression of a genetically encoded calcineurin inhibitor reversed these changes in cultured
neurons treated with Aβ and in APP/PS1 mice (Wu et al., 2010), indicating that calcineurin
activation is downstream of Aβ in causing synapse loss. Here we sought to confirm these
findings using a readily available pharmacological inhibitor of calcineurin, which would be
more suitable than gene transfer for therapeutic administration in patients. We observe a loss
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of dendritic spines on cortical pyramidal neurons in plaque-bearing APP/PS1 mice which is
exacerbated near plaques as has been previously reported in several different transgenic
models (Alpar et al., 2006; Moolman et al., 2004; Spires-Jones et al., 2009; Spires et al.,
2005; Tsai et al., 2004). Calcineurin inhibition with FK506 treatment for 7 days results in a
rescue of spine density in APP/PS1 mice, confirming that calcineurin is an important
downstream effector of Aβ mediated spine loss. Since dendritic spines are the post synaptic
element of over 90% of cortical synapses and newly generated spines do form synapses
(Knott et al., 2006), we interpret these data to mean calcineurin inhibition rapidly
ameliorates synapse loss in AD model mice.
Despite this positive effect on dendritic spine density, this exposure to FK506 treatment did
not reduce dystrophic neurite size or number per plaque, and treatment did not rescue spine
length and morphology changes seen in YFP-APP/PS1 mice. This contrasts with our
previous observation that overexpressing a genetically encoded calcineurin inhibitor directly
in neurons near plaques for 2–4 weeks could ameliorate plaque associated varicosities (Wu
et al., 2010); we interpret this result to suggest that the genetically encoded calcineurin
inhibitor was present continuously for a longer duration and likely at a higher local dose that
we could achieve with daily systemic administration of FK506. Nonetheless, the recovery of
spine density in APP/PS1 mice and even the changes observed in spine morphology in wild
type mice suggest that (1) FK506 is able to access the brain in doses sufficient to impact
dendritic spines, and (2) that calcineurin inhibition can improve Aβ–induced spine loss in an
AD model. The latter point confirms the conclusion that calcineurin is an important
mediator of Aβ–induced spine toxicity using a different mechanism of calcineurin inhibition
(pharmacological rather than genetic) and systemic (rather than local) route of
administration. These results provide an important proof of principle that calcineurin
inhibition is a potent approach to ameliorating Aβ–induced synaptotoxicity.
Our data do not directly address whether FK506 induced morphological changes improve
neural system function. The retention of PSD95 at the synapse depends to some extent on
the shape of the spine (Gray et al., 2006) and calcium compartmentalization is thought to
occur in spines with necks (excluding short stubby spines) (Bloodgood and Sabatini, 2007).
Thus the increased proportion of stubby spines in APP/PS1 mice and in healthy brain with
FK506 treatment may both change dynamics of synaptic proteins and allow more calcium to
enter the parent dendrite. In fact, a loss of decoupling between spine and dendrite calcium as
well as an increase in calcium concentration in a subset of dendrites associated with plaques
has been observed using calcium imaging in APP/PS1 mice in vivo (Kuchibhotla et al.,
2008). On the other hand, a single injection of FK506 (10 mg/kg, i.p.) 6 hours before
behavioral testing has been shown to improve cognition in both APP overexpressing Tg2576
mice and wild-type mice with exogenously injected oligomeric Aβ-induced cognitive
deficits (Dineley et al., 2007; Dineley et al., 2010). FK506 has also been reported to be
neuroprotective in animal models of stroke, trauma, and glaucoma (Hailer, 2008; Huang et
al., 2005; Macleod et al., 2005). Further studies directly comparing behavioral and
morphological outcomes of calcineurin inhibition will be necessary to refine the relationship
between these structural and functional markers of neuroprotection.
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Dendritic spines were imaged in YFP mice (A, B) and YFP mice also expressing APP and
PS1 transgenes that have senile plaques labeled blue with ThioS (C, D). Mice were treated
with either vehicle (A, C) or FK506 (B, D) by i.p. injection for 7 days. Neuron studio
(Rodriguez et al., 2008) was used to reconstruct dendrites and detect spines (bottom panels
show reconstructions). Scale bars represent 20 µm in top panels, 10 µm in bottom panels.
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Analysis of dendritic spine density reveals that in vehicle treated animals, there is a 14%
reduction in spine density in YFP-APP/PS1 mice compared to YFP mice without the APP
and PS1 transgenes (A). This is rescued with 7 days of FK506 treatment. In both vehicle and
FK506 treated groups, spine density correlated with distance from the nearest plaque (B),
indicating the effects of FK506 are greater on dendrites farther from plaques, since many of
the dendrites analyzed had no plaque within measurable distance (greater than 100 µm
away). * p<0.05 post-hoc Tukey-Kramer test.
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Dendritic spines were classified by shape (A) as either mushroom (arrows), thin (arrowhead)
or stubby (asterisk) based on the ratio of head to neck with. Length of dendritic spines was
also measured from the base to tip (B) showing that spines are significantly shorter in YFP-
APP/PS1 mice than in YFP cortical pyramidal neurons with vehicle treatment. Spine length
was reduced by FK506 treatment in YFP mice compared to vehicle treated YFP mice
resulting in lengths even shorter than YFP-APP/PS1 mice, indicating negative effects of this
treatment on healthy brain. The shorter length of spines both with plaques and FK506
treatment appears to be due to a shift in the shapes of spines from longer thin and mushroom
to shorter stubby spines (C). * p<0.005 0001 post-hoc Tukey-Kramer test in B, contingency
table analysis Pearson’s test in C. Scale bar represents 2 µm.
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Dystrophic neurites filled with YFP (green) and axonal dystrophies stained with smi312
(red) were analyzed for size and number per plaque, respectively (A). FK506 treatment does
not rescue either axonal dystrophy number per plaque (B) or YFP dystrophy size (C). Scale
bar represents 5 µm.
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Table 1
Numbers of animals, dendrites, and spines analyzed per group
genotype treatment n animals n dendrites n spines
YFP control 4 88 1565
YFP FK506 3 76 1554
YFP/APP control 8 221 3660
YFP/APP FK506 6 166 2876
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